Cyramza ramucirumab regulatory update

FDA approved Cyramza ramucirumab from Eli Lilly as monotherapy for advanced stomach cancer or gastroesophageal junction adenocarcinoma after prior fluoropyrimidine- or platinum-containing chemotherapy. The label includes a black box warning on the risk of hemorrhage. Lilly plans to launch the product in the "coming weeks" and said it is working on finalizing pricing and patient access programs. The human IgG1 mAb VEGF receptor 2 ( KDR/Flk-1; VEGFR-2) antagonist is also under review in Europe. Lilly plans to submit a sBLA for the product to treat non-small cell lung cancer (NSCLC) next half. ...